Literature DB >> 24077602

Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer.

Haojie Huang1.   

Abstract

The androgen receptor (AR) is a pleiotrophic transcription factor that regulates expression of a large number of genes involved in many diverse cellular processes. The AR activation pathways have been studied extensively. However, the molecular mechanism and biological significance of AR inhibitory signals remain poorly understood. Mukhopadhyay et al. have now identified the nuclear matrix protein scaffold attachment factor B1 (SAFB1) as a novel AR corepressor. The authors found that SAFB1 physically associates with AR protein and inhibits AR transcriptional activity and androgen-sensitive gene expression. SAFB1 had no effect on chromatin occupancy of AR, but silencing of SAFB1 abolished recruitment MST1, a known AR repressor, at AR target loci. They also showed that SAFB1 interacts with EZH2, SUZ12 and EED, three core components of the Polycomb repressive complex 2 (PRC2), which catalyzes the gene repression histone modification H3 lysine 27 trimethylation (H3K27me3). The authors further showed that forced expression of SAFB1 increases H3K27me3 at AR target loci and this effect requires EZH2. Finally, the authors demonstrated that expression of SAFB1 is downregulated in human prostate cancer (PCa) specimens and SAFB1 knockdown results in an aggressive phenotype of PCa. These findings identify SAFB1 as an important node for integration of multiple inhibitory signals of AR, which represents a viable pathway for therapeutic intervention of PCa.

Entities:  

Year:  2013        PMID: 24077602      PMCID: PMC3854040          DOI: 10.1038/aja.2013.116

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  14 in total

1.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

4.  Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer.

Authors:  Laura R Bohrer; Shuai Chen; Timothy C Hallstrom; Haojie Huang
Journal:  Endocrinology       Date:  2010-09-29       Impact factor: 4.736

5.  Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2.

Authors:  Shuai Chen; Laura R Bohrer; Aswathy N Rai; Yunqian Pan; Lu Gan; Xianzheng Zhou; Anindya Bagchi; Jeffrey A Simon; Haojie Huang
Journal:  Nat Cell Biol       Date:  2010-10-10       Impact factor: 28.824

6.  Cooperation between Polycomb and androgen receptor during oncogenic transformation.

Authors:  Jonathan C Zhao; Jianjun Yu; Christine Runkle; Longtao Wu; Ming Hu; Dayong Wu; Jun S Liu; Qianben Wang; Zhaohui S Qin; Jindan Yu
Journal:  Genome Res       Date:  2011-12-16       Impact factor: 9.043

7.  The LATS2/KPM tumor suppressor is a negative regulator of the androgen receptor.

Authors:  Mark Powzaniuk; Sheila McElwee-Witmer; Robert L Vogel; Tadashi Hayami; Su Jane Rutledge; Fang Chen; Shun-Ichi Harada; Azriel Schmidt; Gideon A Rodan; Leonard P Freedman; Chang Bai
Journal:  Mol Endocrinol       Date:  2004-05-06

8.  Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.

Authors:  N K Mukhopadhyay; J Kim; S You; M Morello; M H Hager; W-C Huang; A Ramachandran; J Yang; B Cinar; M A Rubin; R M Adam; S Oesterreich; D Di Vizio; M R Freeman
Journal:  Oncogene       Date:  2013-07-29       Impact factor: 9.867

9.  The pro-apoptotic kinase Mst1 and its caspase cleavage products are direct inhibitors of Akt1.

Authors:  Bekir Cinar; Ping-Ke Fang; Mohini Lutchman; Dolores Di Vizio; Rosalyn M Adam; Natalya Pavlova; Mark A Rubin; Pamela C Yelick; Michael R Freeman
Journal:  EMBO J       Date:  2007-10-11       Impact factor: 11.598

10.  The mutational landscape of lethal castration-resistant prostate cancer.

Authors:  Catherine S Grasso; Yi-Mi Wu; Dan R Robinson; Xuhong Cao; Saravana M Dhanasekaran; Amjad P Khan; Michael J Quist; Xiaojun Jing; Robert J Lonigro; J Chad Brenner; Irfan A Asangani; Bushra Ateeq; Sang Y Chun; Javed Siddiqui; Lee Sam; Matt Anstett; Rohit Mehra; John R Prensner; Nallasivam Palanisamy; Gregory A Ryslik; Fabio Vandin; Benjamin J Raphael; Lakshmi P Kunju; Daniel R Rhodes; Kenneth J Pienta; Arul M Chinnaiyan; Scott A Tomlins
Journal:  Nature       Date:  2012-07-12       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.